Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome

Part of paid clinical trials in Rochester, New York.

Sponsor
University of Rochester
Study ID
NCT01311258
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This study is being performed to develop assays to determine the impact of the therapy patients receive for treatment of AML or MDS and to determine if these tests can identify those patients who are at a greater risk for having their disease relapse.

Key Dates

Start date
Aug 31, 2007
Status verified
Sep 2025
Primary completion
Aug 31, 2030
Completion
Aug 31, 2030

Study Design

Enrollment
400 participants (estimated)

Primary Outcome Measure

Identification of Minimal Residual Disease after treatment for disease [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Rochester Medical CenterRochesterNew York14642
Michael W Becker, MD
[email protected]
585-273-3968
Michael W Becker, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, NY

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
University of Rochester Medical Center· Rochester, NY

Related Studies